Xenon Pharmaceuticals, Inc. (XENE)
40.48
-0.52
(-1.26%)
USD |
NASDAQ |
Nov 13, 16:00
40.00
-0.48
(-1.19%)
After-Hours: 19:59
Xenon Pharmaceuticals Enterprise Value : 3.033B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 3.033B |
| November 12, 2026 | 3.084B |
| November 11, 2026 | 3.193B |
| November 10, 2026 | 3.123B |
| November 09, 2026 | 3.030B |
| November 06, 2026 | 2.905B |
| November 05, 2026 | 2.758B |
| November 04, 2026 | 2.907B |
| November 03, 2026 | 2.812B |
| November 02, 2026 | 2.752B |
| October 30, 2026 | 2.732B |
| October 29, 2026 | 2.744B |
| October 28, 2026 | 2.627B |
| October 27, 2026 | 2.594B |
| October 26, 2026 | 2.571B |
| October 23, 2026 | 2.528B |
| October 22, 2026 | 2.642B |
| October 21, 2026 | 2.588B |
| October 20, 2026 | 2.620B |
| October 19, 2026 | 2.503B |
| October 16, 2026 | 2.346B |
| October 15, 2026 | 2.429B |
| October 14, 2026 | 2.387B |
| October 13, 2026 | 2.438B |
| October 12, 2026 | 2.574B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.636B |
| October 08, 2026 | 2.609B |
| October 07, 2026 | 2.633B |
| October 06, 2026 | 2.649B |
| October 05, 2026 | 2.747B |
| October 02, 2026 | 2.792B |
| October 01, 2026 | 2.881B |
| September 30, 2026 | 2.710B |
| September 29, 2026 | 2.680B |
| September 28, 2026 | 2.628B |
| September 25, 2026 | 2.650B |
| September 24, 2026 | 2.758B |
| September 23, 2026 | 2.613B |
| September 22, 2026 | 2.858B |
| September 21, 2026 | 2.848B |
| September 18, 2026 | 2.922B |
| September 17, 2026 | 4.625B |
| September 16, 2026 | 4.567B |
| September 15, 2026 | 4.521B |
| September 14, 2026 | 4.706B |
| September 11, 2026 | 4.750B |
| September 10, 2026 | 4.765B |
| September 09, 2026 | 4.782B |
| September 08, 2026 | 4.837B |
| September 04, 2026 | 4.857B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Psyence Biomedical Ltd. | -- |
| Aurinia Pharmaceuticals, Inc. | 1.680B |
| enGene Therapeutics, Inc. | -71.62M |
| Medicus Pharma Ltd. | 14.97M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.44M |
| Total Expenses (Quarterly) | 110.44M |
| EPS Diluted (Quarterly) | -1.107 |
| Earnings Yield | -11.62% |
| Normalized Earnings Yield | -11.62 |